Auriga Laboratories Announces FDA Approval Of Liquadd (TM) Oral Solution For The Treatment Of ADHD And Upcoming Product Launch

Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the FDA approval of Liquadd™ (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL indicated for the treatment of Attention Deficit Disorder with Hyperactivity (ADHD).

The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually. Dextroamphetamine is one of the most frequently prescribed molecules for the treatment of ADHD. "Liquadd™ will now provide physicians the proven efficacy of dextroamphetamine in a unique new oral solution form, with our key target consisting of the estimated 5% to 10% of patients that have difficulty swallowing pills. We are excited about expanding the treatment options available to physicians by providing a dextroamphetamine treatment regimen in an easy to swallow form previously not available in the market," said Rick Coulon, Executive Vice President of Sales and Marketing of Auriga.

Liquadd™ will be launched during the 2nd Quarter of 2008. "This new product further solidifies Auriga's commitment to enhance our product portfolio. Currently, we promote several of our products to psychiatrists and pediatricians, and Liquadd™ will be a highly synergistic addition to Auriga's current promotional efforts in these specialties," said Frank Greico, Chief Executive Officer of Auriga.

Amphetamines Have A High Potential For Abuse. Administration Of Amphetamines For Prolonged Periods Of Time May Lead To Drug Dependence And Must Be Avoided. Particular Attention Should Be Paid To The Possibility Of Subjects Obtaining Amphetamines For Non-Therapueitc Use Or Distribution To Others, And The Drugs Should Be Prescribed Or Dispensed Sparingly. Misuse Of Amphetamines May Cause Sudden Death And Serious Cardiovascular Adverse Events.

Do not use Liquad™ in patients with a history of drug abuse. Do not use during or within 14 days following administration of MAO inhibitors; hypertensive crisis may result. Liquadd™ is contraindicated in patients with advance arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma and agitated states.

About Auriga Laboratories™

Auriga Laboratories is a specialty pharmaceutical company building an extensive product portfolio of prescription brands targeting high growth therapeutic categories in the respiratory, dermatology, and psychiatry markets, which have combined annual revenues of more than fifteen billion dollars in the United States. The company's high-growth business model combines driving revenues through a primarily variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral™ for the treatment of Xerostomia, Akurza™, Xyralid™, Zytopic™, and Coraz™ dermatology products, and the Zinx™ Extendryl®, and Levall® Families of products for relief of symptoms associated with a range of acute respiratory diseases.